Prognostic and Predictive Value of Permeability-Glycoprotein, Ki-67, and Interleukin-6 in Lung Cancer Patients
Abstract
Objective: Lung cancer patients often present with metastatic disease at the time of diagnosis, which affects their treatment regimen. Therefore, early diagnosis is crucial for improving patient survival. This study aimed to evaluate the roles of P-glycoprotein (P-gp), Ki-67, and interleukin-6 (IL-6) as diagnostic and predictive indicators in lung cancer. A secondary aim was to assess the prevalence of multi-drug resistance associated with P-gp gene expression in these patients.
Material and Methods: This study included 90 lung cancer patients, consisting of 60 with non-small cell lung cancer (NSCLC) and 30 with small cell lung cancer (SCLC). Additionally, 75 control samples were matched for age, gender, and smoking status. The levels of P-gp, Ki-67, and IL-6 in serum were determined using enzyme-linked immunosorbent assay (ELISA). P-gp gene expression was assessed via reverse transcription-polymerase chain reaction (RT-PCR).
Results: The results indicated that P-gp levels were significantly elevated in SCLC and NSCLC patients (10.35±0.51 ng/ml and 10.06±0.32 ng/ml, respectively) compared to the control group (3.79±0.21 ng/ml; p-value=0.0001). Ki-67 and IL-6 levels also significantly increased in SCLC patients (15.28±0.27 ng/ml and 54.46±2.11 ng/ml, respectively) compared to NSCLC (13.97±0.52 ng/ml and 46.17±1.18 ng/ml, respectively) and the control group (8.43±0.24 ng/ml and 26.40±1.01 ng/ml, respectively; p-value=0.0001). Additionally, mRNA expression of P-gp was significantly higher in lung cancer patients compared to controls.
Conclusion: Elevated levels of P-gp, Ki-67, and IL-6 may serve as useful diagnostic and predictive markers for lung cancer. Moreover, increased mRNA expression of P-gp suggests that lung cancer patients may exhibit resistance to chemotherapy.
Keywords
Full Text:
PDFReferences
Hussain AM, Lafta RK. Cancer trends in Iraq 2000–2016. Oman Med J 2021;36:e219. doi: 10.5001/omj.2021.42.
Al-Khateeb ZD, Mahd LH. Prevalence of lung cancer in al najaf governorate as registered in the middle euphrates oncology center 2019-2020. J Fac Med 2022;64.
Dahir AK, Al-Awad AS, Al-Gazally ME. Investigation the association of the VEGFR-2 and-2578CA polymorphism as a risk factor for incidence of lung cancer in Babylon Province. Indian J Forensic Med Toxicol 2020;14:2391.
Garcia-Valdecasas Gayo S, Ruiz-Alvarez MJ, Gonzalez-Gay D, Ramos-Corral R, Marquez-Lietor E, Del Amo N, et al. CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value. Adv Lab Med 2020;1:20200005. doi: 10.1515/almed-2020-0092.
Shi B, Xu FF, Xiang CP, Jia R, Yan CH, Ma SQ, et al. Effect of sodium butyrate on ABC transporters in lung cancer A549 and colorectal cancer HCT116 cells. Oncol Lett 2020;20:148. doi: 10.3892/ol.2020.12011.
Dallavalle S, Dobričić V, Lazzarato L, Gazzano E, Machuqueiro M, Pajeva I, et al. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist Updat 2020;50:100682. doi: 10.1016/j.drup.2020.100682.
Robinson K, Tiriveedhi V. Perplexing role of P-glycoprotein in tumor microenvironment. Front Oncol 2020;10:265. doi: 10.3389/fonc.2020.00265.
Wang J, Wang H, Zhao L, Fan S, Yang Z, Gao F, et al. Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Anticancer Res 2010;30:3593-8.
Folescu R, Levai CM, Grigoraş ML, Arghirescu TS, Talpoş IC, Gîndac CM, et al. Expression and significance of Ki-67 in lung cancer. Rom J Morphol Embryol 2018;59:227-33.
Wang D, Chen D, Zhang C, Chai M, Guan M, Wang Z, et al. Analysis of the relationship between Ki-67 expression and chemotherapy and prognosis in advanced non-small cell lung cancer. Transl Cancer Res 2020;9:3491.
Wang D, Ye W, Shi Q. Prognostic value of Ki-67 expression in advanced lung squamous cell carcinoma patients treated with chemotherapy. Cancer Manag Res 2021;13:6429-36.
Spiliotaki M, Neophytou CM, Vogazianos P, Stylianou I, Gregoriou G, Constantinou AI, et al. Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab. Mol Oncol 2023;17:792-809.
Chonov DC, Ignatova MMK, Ananiev JR, Gulubova MV. IL-6 activities in the tumour microenvironment. Part 1. Open Access Maced J Med Sci 2019;7:2391.
Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer 2021;21:481-99.
Ke W, Zhang L, Dai Y. The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). Thorac Cancer 2020;11:835-9.
Park CK, Chung C, Oh IJ, Kim YC, Park D, Kim J, et al. Baseline serum interleukin-6 levels predict the response of patients with advanced non-small cell lung cancer to PD-1/PD-L1 inhibitors. Immune Netw 2020;20.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402-8.
Chen P, Kuang P, Wang L, Li W, Chen B, Liu Y, et al. Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure. Transl Lung Cancer Res 2020;9:768. doi: 10.21037/tlcr.2020.03.10.
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist 2019 Jun;2:141. doi: 10.20517/cdr.2019.15.
Janikova M, Zizkova V, Skarda J, Kharaishvili G, Radova L, Kolar Z. Prognostic significance of miR-23b in combination with P-gp, MRP and LRP/MVP expression in non-small cell lung cancer. Neoplasma 2016;63:576-87. doi: 10.4149/neo_2016_419.
Van Niekerk A, Wrzesinski K, Steyn D, Gouws C. A novel NCI-H69AR drug-resistant small-cell lung cancer mini-tumor model for anti-cancer treatment screening. Cells 2023;12:1980. doi: 10.3390/cells12151980.
Hanssen KM, Haber M, Fletcher JI. Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition. Drug Resist Updat 2021;59:100795. doi: 10.1016/j.drup.2021.100795.
Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 2020;21:3233. doi: 10.3390/ijms21093233.
Nair A, Amalraj A, Jacob J, Kunnumakkara AB, Gopi S. Non-curcuminoids from turmeric and their potential in cancer therapy and anticancer drug delivery formulations. Biomolecules 2019;9:13. doi: 10.3390/biom9010013.
Roy S, Kenny E, Kennedy S, Larkin A, Ballot J, De Villarreal MP, et al. MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. Anticancer Res 2007;27:1325-30.
Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 2005;131:355-63. doi: 10.1007/s00432-005-0654-4.
Mannoush SH, Thaker AA, Jabir MS. Inhibition of ovarian cancer cells growth using gold nanoparticles and silica coated gold nanoparticles: In-vitro study. J Pharm Negative Results 2022;13:727-33. doi: 10.4103/jpnr.JPNR_38_20.
Hout DR, Schweitzer BL, Lawrence K, Morris SW, Tucker T, Mazzola R, et al. Performance of a RT-PCR assay in comparison to FISH and immunohistochemistry for the detection of ALK in non-small cell lung cancer. Cancers 2017;9:99. doi: 10.3390/cancers9080099.
Kong J, Qiu Y, Li Y, Zhang H, Wang W. TGF β1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR 145 axis. Biopharm Drug Dispos 2019;40:70-80. doi: 10.1002/bdd.2162.
Mitchell KG, Parra ER, Nelson DB, Zhang J, Wistuba II, Fujimoto J, et al. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non–small cell lung cancer. Int J Clin Exp Pathol 2019;158:911-9.
Li Z, Li F, Pan C, He Z, Pan X, Zhu Q, et al. Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma. Lung Cancer 2021;154:69-75.
Grant L, Banerji S, Murphy L, Dawe DE, Harlos C, Myal Y, et al. Androgen receptor and Ki67 expression and survival outcomes in non-small cell lung cancer. Horm Cancer 2018;9:288-94.
Ozkaya N. Pulmonary pathology journal club: April 2018. Am J Respir Crit Care Med 2018;197:949-52.
Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol 2014;26:38-47.
Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, et al. Circulating interleukin 6 level is a prognostic marker for survival in advanced non-small cell lung cancer patients treated with chemotherapy. Int J Cancer 2013;132:1977-85.
Liu Y, Gao Y, Lin T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor-α (TNF-α) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. Ann Palliat Med 2021;10:12759-66.
Nicola S, Ridolfi I, Rolla G, Filosso P, Giobbe R, Boita M, et al. IL-17 promotes nitric oxide production in non-small-cell lung cancer. J Clin Med 2021;10:4572.
Shill MC, Biswas B, Kamal S, Islam M, Rima SS, Ferdausi FA, Bepari AK. Screening of plasma IL-6 and IL-17 in Bangladeshi lung cancer patients. Heliyon 2023;9.
Kalali D, Hadjiyianni A, Isaakidou A. The use of interleukin-6 as a biomarker of lung cancer: a systematic review and meta-analysis. J Cancer Res Ther 2023;19(Suppl 2):S485-9.
Chen J, Li X, Huang C, Lin Y, Dai Q. Change of serum inflammatory cytokines levels in patients with chronic obstructive pulmonary disease, pneumonia and lung cancer. Technol Cancer Res Treat 2020;19:1533033820951807.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.